Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation

Area of Science:

• Immunology
• Oncology
• Transplantation Medicine

Background:

• Post-transplant lymphoproliferative disorders (PTLD) are a significant risk following solid organ transplantation.
• These disorders range from benign hyperplasia to aggressive lymphomas, frequently linked to Epstein-Barr virus (EBV).
• Immunosuppressive agents used in transplantation can impair immune control over EBV, increasing PTLD risk.

Purpose of the Study:

• To provide an updated review on the pathogenesis and clinical characteristics of PTLD in solid organ transplant recipients.
• To discuss recent advancements in the management strategies for PTLD.
• To highlight emerging therapeutic approaches and future directions in PTLD treatment.

Main Methods:

• Review of current literature on PTLD pathogenesis, clinical features, and management.
• Analysis of established and novel therapeutic interventions.
• Discussion of the role of EBV in PTLD development and treatment.

Main Results:

• Reduction of immunosuppressive therapy is a primary treatment for EBV-positive PTLD, effective in early stages.
• Chemotherapy is utilized when reduced immunosuppression is insufficient or for advanced disease.
• Novel treatments including cytokine modulation, B-cell depletion, and T-cell immunotherapy are under investigation.

Conclusions:

• Early-stage EBV-positive PTLD can respond to reduced immunosuppression, but refractory cases have high mortality.
• Emerging therapies like adoptive T-cell immunotherapy offer potential but require further clinical validation.
• Minimizing excessive immunosuppression and exploring EBV vaccination are crucial for future PTLD prevention and management.